Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for Thromboembolism

Inclusion Criteria: Upcoming surgery for newly diagnosed or potential cancer or relapse / metastasis of cancer that has been treated and diagnosed ≥ 1 year Exclusion Criteria: * Recent (\<6 months) episode of venous thromboembolic disease (Deep vein thrombosis and / or pulmonary embolism and / or thrombosis in a rare location such as visceral or cerebral venous thrombosis) * Pregnancy or pregnancy * Patients on long-term anticoagulation for any reason (MKH, HMB or ABK, DOACs) at prophylactic or therapeutic dose, prior to enrollment in the study. * Active haemorrhage, diagnosed hemorrhagic disorder, thrombocytopenia * Ulcers or vasodilatations of the gastrointestinal tract * Hemorrhagic stroke or surgery in the brain, spine or eye of the last trimester * Bacterial endocarditis or other contraindication to the use of anticoagulant treatment * Creatinine clearance \<20mL / min * Thrombolytic treatment or administration of dextran in the 2 days preceding administration of fondaparinux